CIPO members who enrolled in the VISID study may be experiencing delays in taking part. Some members may not have had any response from study coordinators since the initial email upon registration.
Some study sites are currently experiencing logistical issues regarding contracts and ethics approval. Currently, only 7 sites are actively recruiting patients with more hopefully starting soon. The sites currently recruiting are:
- the Ottawa Hospital
- the University of Ottawa
- CHEO
- SickKids
- University of Alberta
- University of Manitoba
- University of Dalhousie
- CHU Sainte-Justine
About the Study
COVID-19 vaccines are being offered to all eligible Canadians to provide immunity against the SARS-COV-2 virus. However, the clinical trials for these vaccines did not include individuals with low or compromised immune systems. Hence, it is not known how these individuals will respond to these COVID-19 vaccines. The purpose of our study is to fill this gap in knowledge by increasing our understanding of immunocompromised individuals’ response to COVID-19 vaccines and studying the effectiveness and safety of COVID-19 vaccines in this group. This knowledge will inform healthcare practitioners’ decisions with regard to administering COVID-19 vaccines for this group. Additionally, examining the immune responses in individuals with many different kinds of immune system problems will help our investigators tease out which component of the immune system is essential to the normal COVID-19 vaccine response.